Publications en collaboration avec des chercheurs de University College London (29)

2024

  1. Additional file 1 of “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”

    figshare

  2. Additional file 1 of “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”

    figshare

  3. Additional file 2 of “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”

    figshare

  4. Additional file 2 of “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”

    figshare

  5. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)

    European Journal of Cancer, Vol. 204

  6. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients

    Translational Research, Vol. 271, pp. 105-115

2023

  1. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction"

    Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 8

  2. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

    European Journal of Cancer, Vol. 185, pp. 28-39

  3. In the literature: July 2023

    ESMO Open

  4. Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer

    ESMO Open, Vol. 8, Núm. 6

  5. Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer

    European Journal of Surgical Oncology, Vol. 49, Núm. 1, pp. 21-28

  6. The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice

    Cancer Treatment Reviews, Vol. 121

2022

  1. In the literature: February 2022

    ESMO Open

  2. Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible

    ESMO Open

2019

  1. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

    Gynecologic Oncology, Vol. 152, Núm. 1, pp. 53-60

2018

  1. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 29, pp. iv238-iv255

  2. Integration of oncology and palliative care

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii553

  3. Integration of oncology and palliative care: a Lancet Oncology Commission

    The Lancet Oncology, Vol. 19, Núm. 11, pp. e588-e653

2015

  1. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial

    The Lancet Oncology, Vol. 16, Núm. 8, pp. 928-936

2013

  1. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

    European Journal of Cancer, Vol. 49, Núm. 11, pp. 2565-2578